Safety and Efficacy of Tripalmitoleoylglycerol in the Treatment of Dermatitis

Summary

This randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the safety and efficacy of topical palmitoleic acid glyceride supplementation in improving skin barrier impairment associated with chronic dermatitis, with a particular focus on the interaction between physical activity, skin microbiota, and lipid metabolism.

Emerging evidence suggests that regular physical activity reshapes the skin microenvironment, including alterations in sebaceous lipid composition and enrichment of Staphylococcus epidermidis, which possesses lipase activity capable of metabolizing glycerides into bioactive fatty acids. Palmitoleic acid, a key lipid metabolite derived from palmitoleic acid glycerides, has demonstrated anti-inflammatory and barrier-protective properties in preclinical and clinical settings. However, it remains unclear whether restoring exercise-associated lipid metabolites through topical application can improve skin barrier dysfunction in individuals with chronic dermatitis, and whether physical activity status modifies therapeutic efficacy.

Research Objectives：

1. Does topical application of low-concentration palmitoleic acid glyceride improve skin barrier function, as measured by transepidermal water loss (TEWL), in individuals with chronic dermatitis?
2. Does physical activity status influence the therapeutic response to palmitoleic acid glyceride treatment?
3. Are improvements in skin barrier function associated with changes in skin microbiota composition, microbial lipase activity, and lipid metabolism at the skin surface?

Study Design and Group Allocation：

Eligible male/female participants aged 18-59 years with clinical manifestations of chronic dermatitis and evidence of skin barrier impairment will be enrolled. Based on metabolic equivalents (MET) levels outside of daily living activities, participants will be divided into sedentary group and exercise group. Within each stratum, participants will be randomly assigned in a 1:1 ratio to receive either topical palmitoleic acid glyceride or placebo, resulting in four study groups:

1. Inactive Placebo Group: No regular physical activity; topical placebo.
2. Inactive Intervention Group: No regular physical activity; topical tripalmitoleoylglycerol.
3. Active Placebo Group: Regular physical activity; topical placebo.
4. Active Intervention Group: Regular physical activity; topical tripalmitoleoylglycerol.

Participant Procedures：

1. Daily topical application of either 0.5% tripalmitoleoylglycerol or placebo to a predefined skin lesion area for 7 consecutive days.
2. Non-invasive assessment of skin barrier function, including TEWL measurements, at baseline and after completion of the intervention.
3. Clinical evaluation of skin symptoms, including erythema, scaling, and pruritus, using standardized scoring systems (PASI or SCORAD, as appropriate).
4. Collection of skin swab samples for microbiome and metabolomic analyses to assess microbial lipase activity and palmitoleic acid production.
5. A subset of participants will undergo skin biopsy for histological and immunohistochemical analyses.
6. Weekly follow-up assessments to monitor treatment adherence and record any adverse events, particularly local skin reactions.

This study seeks to elucidate a novel exercise-microbiota-lipid axis in skin barrier regulation and to provide translational evidence for metabolite-based therapeutic strategies in chronic inflammatory skin diseases.

Conditions

• Skin Barrier to Water Loss
• PASI /SCORAD Index

Interventions

OTHER

Placebo topical intervention

Placebo topical intervention applied continuously for 7 days (once daily).

OTHER

0.5% Tripalmitoleoylglycerol topical intervention

0.5% Tripalmitoleoylglycerol topical intervention applied continuously for 7 days (once daily).

Sponsors & Collaborators

• Shenzhen People's Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

59 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-01-10

Primary Completion

2026-03-05

Completion

2026-03-08

Countries

• China

Study Locations